Version May 2024
| Clot phase | Parameter | Measurement | TEG abbreviation | ROTEM abbreviation | Enzymatic stage | Abnormalities |
| Clot initiation | Clotting time | Time from start of sample to 2 mm clot amplitude | Reaction time (R) | Clot time (CT) | Early activation of clotting cascade resulting in initial thrombin burst | Prolonged by clotting factor deficiencies, anticoagulants, and hypofibrinogenemia. Shortened in hypercoagulable states. |
| Clot kinetics | Clot formation time | Time from 2 to 20 mm clot amplitude | Clot formation time (K) | Clot formation time (CFT) | Clot potentiation by activation of platelets and thrombin-mediated cleavage of soluble fibrinogen | Prolonged by clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction. |
| Angle | Angle of tangent line from 2 to 20 mm clot formation | Alpha angle | Alpha angle | Abnormally low in clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction. | ||
| Clot strength | Maximal clot strength | Amplitude measured at peak clot strength | Maximal amplitude (MA) | Maximal clot firmness (MCF) | Maximal clot strength achieved via GP IIb/IIIa-mediated platelet-fibrin interactions | Abnormally low in hypofibrinogenemia, thrombocytopenia, or platelet dysfunction. |
| Clot viscoelasticity | Calculated from maximal amplitude | G | Maximal clot elasticity (MCE) | Abnormally high in platelet hypercoagulability. | ||
| Clot lysis | Clot lysis | Percentage of loss of amplitude at fixed time after maximal amplitude | Lysis at 30 minutes (LY30), estimated percentage of lysis (EPL) | Lysis index at 30 minutes (LI30), maximal lysis (ML) | Activation of fibrinolytic system | Abnormally high in enzymatic or mechanical hyperfibrinolysis. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
